No connection

Search Results

SBFM

BEARISH
$1.03 Live
Sunshine Biopharma, Inc. · NASDAQ
Target $5.6 (+443.7%)
$0.95 52W Range $2.43

At a glance

Key valuation, profitability, growth, and risk metrics.

Updated Apr 19, 2026
Market cap
$5.05M
P/E
N/A
ROE
-25.7%
Profit margin
-16.5%
Debt/Equity
0.04
Dividend yield
N/A

AI Analysis

AI-powered fundamental assessment

Confidence
95%
SBFM exhibits critical financial distress, highlighted by a Piotroski F-Score of 1/9, indicating severe fundamental weakness. While the company maintains a strong current ratio (4.17) and very low debt, these are overshadowed by negative revenue growth (-10.60%), consistent earnings misses, and a catastrophic long-term price collapse (-100% over 5 years). The single analyst's 'strong buy' recommendation and $5.60 target appear to be extreme outliers that contradict the deterministic data. The stock is trading at a deep discount to book value (P/B 0.22), but this is typical for distressed micro-cap biotech firms with failing growth trajectories.

Key Strengths

Very low leverage (Debt/Equity 0.04)
Strong short-term liquidity (Current Ratio 4.17)
Positive gross margins (33.76%)
Extremely low Price-to-Book ratio (0.22)
Low Price-to-Sales ratio (0.14)

Key Risks

Severe fundamental weakness (Piotroski F-Score 1/9)
Negative revenue growth (YoY -10.60%)
Consistent and significant earnings misses (Average surprise -67.81%)
Extreme long-term capital erosion (-99.9% 3Y change)
High volatility and micro-cap liquidity risk

Performance Snowflake

Multi-dimensional analysis across 5 key categories

Overall
14
Weak
Value
40
Future
10
Past
5
Health
15
Dividend
0
AI Verdict
High Risk / Speculative
Key drivers: Piotroski F-Score 1/9, Negative Revenue Growth, Total 5Y Price Collapse, Consistent EPS Misses
Confidence
90%
Value
40/100

Trades at a massive discount to assets, but assets may be impaired or non-productive.

Positives
  • P/B of 0.22
  • P/S of 0.14
Watchpoints
  • No P/E ratio
  • No Graham Number available
Future
10/100

Growth metrics are negative across both YoY and Q/Q timeframes.

Positives
No standout positives identified.
Watchpoints
  • Revenue growth -10.60%
  • Q/Q Revenue growth -10.61%
  • Negative profit margins
Past
5/100

Historical price performance indicates a total loss of investor confidence.

Positives
No standout positives identified.
Watchpoints
  • 5Y Change -100%
  • 3Y Change -99.9%
  • 6M Change -50.7%
Health
15/100

Liquidity is present, but operational health is critical.

Positives
  • Low Debt/Equity
  • High Current Ratio
Watchpoints
  • Piotroski F-Score 1/9
  • Negative ROE (-25.68%)
Dividend
0/100

Non-dividend paying growth/speculative stock.

Positives
No standout positives identified.
Watchpoints
  • No dividend paid
  • 0/100 Dividend Strength

Stock Price & Analyst Targets

Real-time price movements and analyst price targets

Current Price
$1.03
Analyst Target
$5.6
Upside/Downside
+443.7%

Multi-Horizon Performance vs Peers

Price momentum across 5Y → 1W horizons for SBFM and closest competitors.

Updated 2026-04-17
SBF
Sunshine Biopharma, Inc.
Primary
5Y
-100.0%
3Y
-99.9%
1Y
-17.6%
6M
-50.7%
1M
-6.4%
1W
+3.2%
CLG
CollPlant Biotechnologies Ltd.
Peer
5Y
-97.4%
3Y
-95.1%
1Y
-85.0%
6M
-83.7%
1M
-43.0%
1W
-33.0%
INB
Intelligent Bio Solutions Inc.
Peer
5Y
-100.0%
3Y
-99.3%
1Y
-79.8%
6M
-77.0%
1M
-39.7%
1W
-10.6%
MLE
Moolec Science SA
Peer
5Y
-99.5%
3Y
-98.7%
1Y
-93.0%
6M
-33.2%
1M
-26.5%
1W
-34.3%
JAG
Jaguar Health, Inc.
Peer
5Y
-100.0%
3Y
-100.0%
1Y
-92.8%
6M
-82.2%
1M
-34.7%
1W
-7.8%

Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.

Historical Performance Trends

Long-term financial metrics and growth patterns

Revenue & Net Income

Profit & Operating Margins

Return on Equity (ROE)

Quarterly Revenue Growth

Historical data shows last 12 quarters (3 years)

Valuation Metrics

Key valuation ratios and pricing indicators

P/E Ratio
N/A
Forward P/E
0.01
PEG Ratio
N/A
P/B Ratio
0.22
P/S Ratio
0.14
EV/Revenue
-0.09
EV/EBITDA
0.78
Market Cap
$5.05M

Profitability

Profit margins and return metrics

Profit Margin -16.46%
Operating Margin -19.33%
Gross Margin 33.76%
ROE -25.68%
ROA -9.23%

Growth

Revenue and earnings growth rates

Revenue Growth -10.6%
Earnings Growth N/A
Q/Q Revenue Growth -10.61%
Q/Q Earnings Growth N/A

Financial Health

Balance sheet strength and liquidity metrics

Debt/Equity
0.04
Low debt
Current Ratio
4.17
Strong
Quick Ratio
1.95
Excellent
Cash/Share
$1.86

Financial Statement Flow

Interactive flow visualization showing how money moves through the company Q4 2025

Revenue
$0.0B
Gross Margin
35.3%
Op. Margin
-19.3%
Net Margin
-25.0%
Total Assets
$0.0B
Liabilities
$0.0B
Equity
$0.0B
Debt/Equity
0.31x
Operating CF
$-0.0B
CapEx
$-0.0B
Free Cash Flow
$-0.0B
FCF Yield
102%

Quarterly Earnings History

EPS performance vs analyst estimates

2026-04-03
$-0.46
-70.4% surprise
2025-11-13
$-0.19
-46.1% surprise
2025-08-12
$-0.39
-254.6% surprise
2024-11-05
$-0.94
+99.8% surprise

Healthcare Sector Comparison

Comparing SBFM against 447 companies in the Healthcare sector (26 bullish, 140 neutral, 281 bearish)
Return on Equity (ROE)
-25.68%
This Stock
vs
-97.42%
Sector Avg
-73.6% (Below Avg)
Profit Margin
-16.46%
This Stock
vs
-14.95%
Sector Avg
+10.1% (Superior)
Debt to Equity
0.04
This Stock
vs
3.06
Sector Avg
-98.8% (Less Debt)
Revenue Growth
-10.6%
This Stock
vs
147.85%
Sector Avg
-107.2% (Slower)
Current Ratio
4.17
This Stock
vs
4.68
Sector Avg
-10.9% (Weaker)

Similar Companies

Peer comparison within the same industry

Recent Insider Trading

Insider buy and sell transactions from the last 6 months

NATAN DAVID
Director
Stock Award
2026-04-14
100,000 shares
Insider transactions can signal confidence or concerns about company prospects

Past News Coverage

Recent headlines mentioning SBFM from our newsroom.

Newest → oldest
TradingGPT V2 Copilot
Fundamentals • Valuation • Risk
Hi! I'm your fundamentals copilot.

Ask me to:
• Summarize the business quality
• Review valuation and multiples
• Highlight risks and red flags
• Explain growth and margin trends
Home
Terminal
AI
Markets
Profile